Timoptol

Timolol maleate

Reduction of elevated IOP in patients w/ ocular HTN, chronic open-angle glaucoma, aphakia w/ glaucoma, some secondary glaucoma, narrow angles & a history of spontaneous or iatrogenically induced narrow-angle closure in the opposite eye in whom reduction of IOP is necessary. Concomitant therapy in patients w/ ped glaucoma who are inadequately controlled w/ other antiglaucoma therapy.

Initially 1 drop of 0.25% in the affected eye(s) bd. If clinical response is not adequate, dosage may be changed to 1 drop of 0.5% soln in the affected eye(s) bd. If needed, concomitant therapy w/ other agent(s) for lowering IOP may be given w/ Timoptol. Use of 2 topical β-adrenergic blocking agents is not recommended. Transfer patient from other therapy Discontinue after proper dosing on 1 day & start treatment w/ Timoptol on the following day w/ 1 drop of 0.25% Timoptol in the affected eye bd. Childn Initially 1 drop of 0.25% in the affected eye(s) 12 hrly, in addition to other antiglaucoma medication. Dosage may be increased to 1 drop of 0.5% in the affected eye(s) 12 hrly if necessary.

Hypersensitivity. Reactive airway disease, bronchial asthma or a history of bronchial asthma, severe COPD. Sinus bradycardia, sino-atrial block, 2nd & 3rd degree AV block, overt cardiac failure, cardiogenic shock.

Adequately control cardiac failure prior to initial therapy. History of CV disease; monitor signs of deterioration & pulse rates. 1st degree heart block. Asthma. Mild or moderate COPD. Severe peripheral circulatory disturbance or disorders eg, severe forms of Raynaud's disease or syndrome. Spontaneous hypoglycemia or diabetes. Masking of clinical signs of hyperthyroidism (eg, tachycardia). Avoid abrupt w/drawal in patients suspected of developing thyrotoxicosis. Surgical anesth. Use w/ miotic to reduce elevated IOP in angle-closure glaucoma. Choroidal detachment. Remove soft contact lenses prior to administration; reinsert after 15 min. History of atopy or a history of severe anaphylactic reaction to a variety of allergens. Pregnancy & lactation. Childn.

Ocular irritation including burning & stinging, conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity & dry eyes. Visual disturbances, including refractive changes (due to w/drawal of miotic therapy in some cases), diplopia, ptosis, choroidal detachment following filtration surgery, tinnitus; bradycardia, arrhythmia, hypotension, syncope, heart block, CVA, cerebral ischemia, CHF, palpitation, cardiac arrest, edema, claudication, Raynaud's phenomenon, cold hands & feet; bronchospasm (predominantly in patients w/ preexisting bronchospastic disease), resp failure, dyspnea, cough; headache, asthenia, fatigue, chest pain; alopecia, psoriasiform rash or exacerbation of psoriasis; signs & symptoms of allergic reactions including anaphylaxis, angioedema, urticaria, localized & generalized rash; dizziness, depression, insomnia, nightmares, memory loss, increase in signs & symptoms of myasthenia gravis, paresthesia; nausea, diarrhea, dyspepsia, dry mouth, abdominal pain; decreased libido, Peyronie's disease, sexual dysfunction; SLE; myalgia.

Epinephrine. Potentiated systemic β-blockade (eg, decreased heart rate) w/ CYP2D6 inhibitors (eg, quinidine & SSRIs) & timolol. Additive effects & production of hypotension &/or marked bradycardia w/ oral Ca entry blocker, catecholamine-depleting drugs, antiarrhythmics, parasympathomimetics or β-adrenergic blocking agents.

Antiglaucoma Preparations

S01ED01 - timolol ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

POM